Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 12, 2016, Pages 1216-1227

  Sotomi, Yohei ^a   Ishibashi, Yuki ^b   Suwannasom, Pannipa ^a,b,c   Nakatani, Shimpei ^b   Cho, Yun Kyeong ^b   Grundeken, Maik J ^a   Zeng, Yaping ^b   Tateishi, Hiroki ^b   Smits, Pieter C ^d   Barragan, Paul ^e   Kornowski, Ran ^f   Gershlick, Anthony H ^g   Windecker, Stephan ^h   van Geuns, Robert Jan ^b   Bartorelli, Antonio L ⁱ   de Winter, Robbert J ^a   Tijssen, Jan ^a   Serruys, Patrick W ^j   Onuma, Yoshinobu ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d Maasstad Hospital   (Netherlands)

^e Polyclinique les Fleurs   (France)

^f RABIN MEDICAL CENTER   (Israel)

^g GLENFIELD HOSPITAL   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

bioresorbable vascular scaffold; drug eluting stent(s); intravascular ultrasound

Indexed keywords

ADULT; ARTICLE; BIORESORBABLE VASCULAR STENT; CITRIC ACID CYCLE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; DEVICE SAFETY; DIABETES MELLITUS; DRUG DELIVERY DEVICE; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; METAL STENT; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CORONARY DISEASE; DEVICES; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; INTERVENTIONAL ULTRASONOGRAPHY; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; PROSTHESIS DESIGN; RISK FACTOR; STATISTICAL MODEL; STENT; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT; EVEROLIMUS; METAL;

ABSORBABLE IMPLANTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84994044884     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.03.022     Document Type: Article

References (23)

1. 1 Serruys, P.W., Onuma, Y., Garcia-Garcia, H.M., et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 9 (2014), 1271–1284.
2. 2 Onuma, Y., Serruys, P.W., Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?. Circulation 123 (2011), 779–797.
3. 3 Diletti, R., Serruys, P.W., Farooq, V., et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the Xience everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 164 (2012), 654–663.
4. 4 Serruys, P.W., Chevalier, B., Dudek, D., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385 (2015), 43–54.
5. 5 Brugaletta, S., Gomez-Lara, J., Diletti, R., et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 79 (2012), 219–228.
6. 6 Zhang, Y.J., Bourantas, C.V., Muramatsu, T., et al. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention 10 (2014), 672–680.
7. 7 Kimura, T., Kozuma, K., Tanabe, K., et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 36 (2015), 3332–3342.
8. 8 Gao, R., Yang, Y., Han, Y., et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol 66 (2015), 2298–2309.
9. 9 Ellis, S.G., Kereiakes, D.J., Metzger, D.C., et al. Everolimus-eluting bioresorbable scaffolds for coronary artery Disease. N Engl J Med 373 (2015), 1905–1915.
10. 10 Ishibashi, Y., Nakatani, S., Sotomi, Y., et al. Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 Year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). J Am Coll Cardiol Intv 8 (2015), 1715–1726.
11. 11 Inaba, S., Mintz, G.S., Farhat, N.Z., et al. Impact of positive and negative lesion site remodeling on clinical outcomes: insights from PROSPECT. J Am Coll Cardiol Img 7 (2014), 70–78.
12. 12 Mintz, G.S., Nissen, S.E., Anderson, W.D., et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37 (2001), 1478–1492.
13. 13 de Jaegere, P., Mudra, H., Figulla, H., et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 19 (1998), 1214–1223.
14. 14 Mintz, G.S., Popma, J.J., Pichard, A.D., et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation 91 (1995), 1959–1965.
15. 15 Garcia-Garcia, H.M., Costa, M.A., Serruys, P.W., Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J 31 (2010), 2456–2469.
16. 16 de Ribamar Costa, J. Jr., Mintz, G.S., Carlier, S.G., et al. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J 153 (2007), 297–303.
17. 17 He, Y., Maehara, A., Mintz, G.S., et al. Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion. Am J Cardiol 105 (2010), 1272–1275.
18. 18 Lee, W.S., Kim, S.W., Lee, K.J., Kim, T.H., Kim, C.J., Ryu, W.S., Under-expansions of drug eluting stents in patients with acute coronary syndrome are associated with plaque components as well as vessel size or plaque burden. Circulation, 120, 2009 S913.
19. 19 Onuma, Y., Serruys, P.W., Gomez, J., et al., ABSORB Cohort A and B investigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 78 (2011), 3–12.
20. 20 Tanimoto, S., Bruining, N., van Domburg, R.T., et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 52 (2008), 1616–1620.
21. 21 Ormiston, J.A., Serruys, P.W., Regar, E., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371 (2008), 899–907.
22. 22 Onuma, Y., Serruys, P.W., Perkins, L.E., et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122 (2010), 2288–2300.
23. 23 Onuma, Y., Serruys, P.W., Muramatsu, T., et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the Absorb everolimus-eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). J Am Coll Cardiol Img 7 (2014), 1400–1411.